Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Research UK

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in phase 3 breast cancer study

More than two million cases of breast cancer were diagnosed globally in 2022

- PMLiVE

UK study reveals significantly higher risk of second cancers among breast cancer survivors

Breast cancer is currently the most commonly diagnosed cancer in the UK, affecting around 56,000 people annually

- PMLiVE

AstraZeneca’s Truqap plus Faslodex receives CHMP recommendation for advanced breast cancer

More than 550,000 new cases of breast cancer were diagnosed in Europe in 2022

- PMLiVE

UK universities awarded over £58m by Cancer Research UK for clinician scientist training

The funding builds on the charity’s previous Clinical Academic Training Programme Award investment in 2019

- PMLiVE

Single genetic test could replace current standard for diagnosing rare developmental disorders

The single genetic test could potentially replace the current standard and reduce costs for the NHS

- PMLiVE

ICR study shows how dormant breast cancer cells can be targeted to prevent relapse

Oestrogen receptor positive breast cancer accounts for up to 80% of all breast cancers cases

- PMLiVE

Study reveals molecular signatures driving immune cell attacks in chronic neurological diseases

MS is a chronic neurological disease that affects more than two million people worldwide

- PMLiVE

Cambridge study reveals potential biomarker and target for long COVID treatments

The pro-inflammatory molecule, IFN-Y, persisted until symptoms improved in patients

- PMLiVE

ICR scientists identify new way to study important driver of breast cancer

Researchers used a technique to identify specific molecular details of biotin-labelled proteins

- PMLiVE

ICR researchers reveal how advanced breast cancers become resistant to hormone therapy

F404 mutations combined with pre-existing mutations caused resistance to fulvestrant

- PMLiVE

WHO reveals growing global cancer burden in line with World Cancer Day

The three most commonly occurring cancers in 2022 were lung, breast and colorectal cancer

- PMLiVE

Researchers uncover role of inherited genetic variants in rare blood cancer

There are around 4,000 cases of myeloproliferative neoplasms in the UK each year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links